Iruplinalkib, a novel ALK inhibitor, was more effective than crizotinib in a phase 3 trial of patients with advanced, ALK-positive non-small cell lung cancer.
Researchers investigated the effects of multidisciplinary clinical management of IMDC in patients with NSCLC undergoing treatment with immune checkpoint inhibitors.
Adding ipilimumab to treatment with nivolumab does not provide a clinically meaningful benefit in patients with certain cancers, a meta-analysis suggests.